Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

From the Editors: PCSK9 inhibitors & cardiovascular disease: heralding a new therapeutic era

PCSK9 Forum Editors overview recent developments in PCSK9 science and therapeutics, culminating in regulatory approval of the first two PCSK9 monoclonal antibodies earlier this year. The editors highlight severe familial hypercholesterolaemia (FH, inherited high cholesterol), including homozygous FH, as a key priority. Additionally, there is a potential role for these novel agents in high-risk patients with established cardiovascular disease who cannot tolerate statin therapy.

Register or Log In to download this Hot off the Press review